KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/02/17 | $76,000,000 |
Alexandria Real Estate Equities ARCH Venture Partners Flagship Ventures Polaris Partners | undisclosed | |
| 09/28/18 | $80,000,000 | Series C |
Alexandria Real Estate Equities ARCH Venture Partners Baillie Gifford Cowen Healthcare Investments Flagship Pioneering Invus Lilly Asia Ventures Polaris Partners | undisclosed |
